Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis Qian ZhangWei WangChun-Hua Xu Review Article Open access 25 November 2021 Pages: 1 - 9
Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis Takanori MukozuHidenari NagaiYoshinori Igarashi Original Article 10 October 2021 Pages: 11 - 20
Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case–control study Takenori IchimuraMiwa HinataShinya Suzuki Original Article Open access 14 October 2021 Pages: 21 - 30
Abemaciclib is synergistic with doxorubicin in osteosarcoma pre-clinical models via inhibition of CDK4/6–Cyclin D–Rb pathway Deli WangHaiqin Bao Original Article 16 October 2021 Pages: 31 - 40
Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury Sandra HeuschkelTheresa KretschmannMalte von Bonin Original Article Open access 20 October 2021 Pages: 41 - 48
A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies Antoinette R. TanNancy ChanJanice M. Mehnert Original Article 20 October 2021 Pages: 49 - 58
4-(N)-Docosahexaenoyl 2’, 2’-difluorodeoxycytidine induces immunogenic cell death in colon and pancreatic carcinoma models as a single agent Stephanie HufnagelHaiyue XuZhengrong Cui Original Article 26 October 2021 Pages: 59 - 69
Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants Jennifer E. HibmaMelissa O’GormanYazdi K. Pithavala Original Article Open access 26 October 2021 Pages: 71 - 81
Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms Keishi YoshidaAtsushi FujitaYasuhiko Itoh Original Article 26 November 2021 Pages: 83 - 91
Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose–escalation phase 1 trial Amita PatnaikGlen J. WeissJasgit C. Sachdev Original Article Open access 08 November 2021 Pages: 93 - 103
A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer Sukhmani K. PaddaKaren L. ReckampHeather A. Wakelee Original Article Open access 13 November 2021 Pages: 105 - 115
A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib E. M. ToscaN. TerranovaI. Poggesi Original Article 17 November 2021 Pages: 117 - 128
Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma Takafumi IdeMayu OsawaHeather E. Vezina Original Article Open access 26 November 2021 Pages: 129 - 140
Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers Xue ChenFeng YangJing Wang Clinical Trial Report 01 December 2021 Pages: 141 - 148
Retraction Note to: Linc‑ROR confers gemcitabine resistance to pancreatic cancer cells via inducing autophagy and modulating the miR‑124/PTBP1/PKM2 axis Chenggang LiZhiming ZhaoRong Liu Retraction Note 18 October 2021 Pages: 149 - 149